RH Capital closed an oversubscribed second fund, bringing total assets under management to over $40 million to tackle reproductive and maternal health equity. In 2019, RH Capital raised a small proof of concept fund with around $5M and has now closed fund II with an additional $38.5M, Femtech Insider reports. The fund’s lead investors include Tara Health Foundation, Skoll Foundation, The Impact Seat Foundation, Houssian Foundation, Argosy Foundation and The Case for Her.
RH Capital is a female-led impact venture capital firm investing in women’s health innovations that improve access, affordability, choice, and health outcomes in the US and globally. Its primary areas of focus are contraception and maternal health, in addition to investing across women’s health more broadly. At the core of RH Capital’s investment strategy is a commitment to health equity and a belief that reproductive and maternal health care are essential health care.
To date, RH Capital has invested in 15 portfolio companies, including Ovia Health which was acquired by LabCorp in 2021, Nurx which merged with Thirty Madison in 2022, and Cirqle Biomedical, which just announced an exclusive licensing deal with Organon. The fund invests across the healthcare spectrum, from biotech and medical devices to digital health and services, with a particular focus on underserved and marginalized populations (Medicaid, BIPOC, rural, etc.) to significantly reduce health disparities in those communities.
RH Capital is a fund of Rhia Ventures, a non-profit whose mission is to leverage capital to affect positive change in reproductive and maternal health. Read more.
